Recursion Pharmaceuticals, Inc. RXRX Indefinite- lived intangible impairment
Indefinite- lived intangible impairment at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsGrossExcludingGoodwill.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s indefinite- lived intangible impairment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s indefinite- lived intangible impairment?
- Recursion Pharmaceuticals, Inc. (RXRX) reported indefinite- lived intangible impairment of $381.71M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s indefinite- lived intangible impairment changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s indefinite- lived intangible impairment increased by 2.0% year-over-year, from $374.36M to $381.71M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s indefinite- lived intangible impairment?
- Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s indefinite- lived intangible impairment has grown at a 192.1% compound annual growth rate (CAGR), from $1.82M to $385.68M.